RHRichard E. Haaland

Richard E. Haaland

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Richard E. Haaland has a total of 90 co-authors. Here are the top co-authors by number of shared publications:

  • Amy Martin

    Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA

    7 shared publications
  • Chuong Dinh

    Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA

    7 shared publications
  • Christopher Conway-Washington

    The Hope Clinic of the Emory Vaccine Center, Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA

    4 shared publications
  • LaShonda Hall

    The Hope Clinic of the Emory Vaccine Center, Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine , Atlanta, GA , USA

    4 shared publications
  • Angela Holder

    Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention , 1600 Clifton Road NE, M/S H17-3, Atlanta, GA , USA

    3 shared publications
  • Colleen F. Kelley

    The Hope Clinic of the Emory Vaccine Center, Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA; Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USA

    3 shared publications

Latest Publications

  • Open Access

    A Highly Sensitive and Specific Rapid Lateral Flow Assay for the HIV Integrase Strand Transfer Inhibitors Bictegravir, Cabotegravir, and Dolutegravir

    by Xierong Wei, Ae S. Youngpairoj, Richard Haaland, Chuong Dinh, Hetal K. Patel, Jose J. Perez, Kristin Brown, Thomas H. Vanderford, Jeffrey A. Johnson

    Background: Second‐generation HIV‐1 integrase strand transfer inhibitors (INSTIs)—bictegravir (BIC), cabotegravir (CAB), and dolutegravir (DTG)—are leading components of highly potent antiretroviral therapy, and CAB is also used for long‐acting chemoprevention. Rapid detection of clinically relevant INSTI concentrations could support point‐of‐care assessment and real‐time clinical decision‐making. We developed a lateral flow assay (LFA) that detects BIC, CAB, and DTG in whole blood and plasma and evaluated its performance against predefined concentration thresholds and high‐performance liquid chromatography‐tandem mass spectrometry (LC‐MS/MS). Methods: A single LFA cassette design was developed using a monoclonal antibody to distinguish BIC, CAB, and DTG concentrations below trough, at minimal‐to‐moderate trough, and at ideal concentrations. LFA results were read visually at 20 min and were compared with LC‐MS/MS–quantified INSTI concentrations for 124 clinical plasma specimens. Results: For 24 plasma samples from US participants receiving treatment involving one of the three INSTIs, the LFA interpretations matched all LC‐MS/MS results except for one DTG specimen, which was interpreted by LFA as 1.0–1.6 μg/mL but measured 2.1 μg/mL by LC‐MS/MS. Among 100 plasma remnants from routine national surveillance in Eswatini, the LFA correctly interpreted DTG concentrations in 95 specimens. Four specimens had DTG LC‐MS/MS concentrations slightly above the LFA‐determined range, differing by ≤ 0.1 μg/mL, and one specimen measured at 1.20 μg/mL by LC‐MS/MS was interpreted as ≥ 1.6 μg/mL by LFA. In total, 6 of 124 specimens (4.8%) had LFA‐interpreted INSTI concentrations that varied slightly from the LC‐MS/MS results, with no statistically significant difference in overall performance by Wilcoxon signed‐rank test ( W = 8.00, p = 0.94, one‐tailed). Conclusions: The LFA design successfully provided clinically useful interpretations of BIC, CAB, and DTG concentrations with minor discrepancies in < 5% of samples. Importantly, all low‐concentration samples of < 1 μg/mL were correctly interpreted by LFA. The assay shows promise as a point‐of‐care tool for assessing clinically relevant INSTI concentrations.

  • Open Access

    Oral Fluid Concentrations of Tenofovir and Emtricitabine for Monitoring HIV Antiretroviral Adherence: Findings From a Randomized Trial with Directly Observed Therapy (TARGET Study)

    by Xin Niu, Tiancheng E Edwards, Jeannette A Dienhart, Richard E Haaland, Oraphan Siriprakaisil, Pra-Ornsuda Sukrakanchana, Tim R Cressey, Paul K Drain

    Background: Early identification of non-adherence to daily antiretroviral therapies may facilitate targeted transition to long-acting HIV regimens for individuals most likely to benefit. This study evaluated the feasibility of detecting emtricitabine (FTC) and tenofovir (TFV) in oral fluids to monitor daily oral pre-exposure prophylaxis (PrEP) adherence. Methods: We collected 241 oral fluids from 22 HIV-negative adults randomized to 2, 4, or 7 doses/week of oral PrEP with FTC/TDF for directly observed therapy. Generalized Estimating Equations were used to examine the associations between FTC/TFV detectability and three dimensions of PrEP adherence: dosing recency, cumulative dosing time, and dosing frequency. We also assessed the diagnostic accuracy of FTC levels in oral fluids for predicting daily oral PrEP non-adherence (time since the last dose >24 hours). Results: Among 165 oral fluids with a time since the last dose within 48 hours, 9.0% had detectable TFV, and 53.3% had detectable FTC. Compared with oral fluids collected within 24 hours since the last dose, those collected between 24 and 48 hours since the last dose had significantly lower odds of having detectable FTC (odds ratio: 0.21, 95% confidence interval [CI]: 0.11–0.38). An FTC threshold of <7.5 ng/mL achieved a sensitivity of 90% (95% CI: 84%–94%) and a specificity of 65% (95% CI: 57%–74%) for identifying recent PrEP non-adherence. Conclusions: FTC can be detected in oral fluids and may be a promising pharmacologic marker for identifying recent PrEP non-adherence as early as one dose missed. TFV had lower concentrations in oral fluids, and is not suitable for adherence monitoring. Clinical Trials Registration. NCT0301260.


  • Open Access

    Pharmacokinetics of single dose doxycycline in the rectum, vagina, and urethra: implications for prevention of bacterial sexually transmitted infections

    by Richard E. Haaland, Jeffrey Fountain, Tiancheng E. Edwards, Chuong Dinh, Amy Martin, Deborah Omoyege, Christopher Conway-Washington, Colleen F. Kelley, Walid Heneine


  • Open Access

    Pharmacology of boosted and unboosted integrase strand transfer inhibitors for two-dose event-driven HIV prevention regimens among men

    by Richard E Haaland, Jeffrey Fountain, Amy Martin, Chuong Dinh, Angela Holder, Tiancheng E Edwards, L Davis Lupo, LaShonda Hall, Christopher Conway-Washington, Ivana Massud, et al.

    Background: Event-driven HIV prevention strategies are a priority for users who do not require daily pre-exposure prophylaxis (PrEP). Regimens containing integrase strand transfer inhibitors (INSTIs) are under evaluation as alternatives to daily PrEP. To better understand INSTI distribution and inform dosing selection we compared the pharmacology of two-dose boosted elvitegravir and unboosted bictegravir regimens in MSM. Materials and methods: Blood, rectal and penile secretions and rectal biopsies were collected from 63 HIV-negative MSM aged 18–49 years. Specimens were collected up to 96 h after two oral doses of tenofovir alafenamide and emtricitabine with elvitegravir boosted by cobicistat or unboosted bictegravir given 24 h apart. Antiretroviral drugs were measured by LC-MS. Results: Mean bictegravir plasma concentrations remained above the 95% protein-adjusted effective concentration 96 h after dosing [273 (95% CI: 164–456) ng/mL] whereas elvitegravir plasma concentrations became undetectable 48 h after the second dose. Bictegravir and elvitegravir reached rectal tissues within 2 h after the first dose, and elvitegravir tissue concentrations [1.07 (0.38–13.51) ng/mg] were greater than bictegravir concentrations [0.27 (0.15–0.70) ng/mg]. Both INSTIs became undetectable in tissues within 96 h. Elvitegravir and bictegravir were not consistently detected in penile secretions. Conclusions: Whereas bictegravir plasma concentrations persist at least 4 days after a two-oral-dose HIV prophylaxis regimen, elvitegravir accumulates in mucosal tissues. Differing elvitegravir and bictegravir distribution may result in variable mucosal and systemic antiviral activity and can inform dosing strategies for event-driven HIV prevention.


  • Open Access

    Short Communication: Evaluation of Antiretroviral Drug Concentrations in Minimally Invasive Specimens for Potential Development of Point-of-Care Drug Assays

    by Richard E. Haaland, Amy Martin, Melkam Mengesha, Chuong Dinh, Jeffrey Fountain, L. Davis Lupo, LaShonda Hall, Christopher Conway-Washington, Colleen F. Kelley

    Point-of-care (POC) tests for antiretroviral drugs (ARVs) could help improve individual adherence. This study sought to define the utility of urine, blood, and buccal swabs as minimally invasive specimens amenable to development of POC tests for ARVs. Urine, dried blood spots (DBS) and buccal swabs were collected from 35 HIV-negative men between 2 and 96 h after a single dose of tenofovir (TFV) alafenamide/emtricitabine (FTC)/elvitegravir (EVG)/cobicistat and darunavir (DRV). ARV concentrations were measured by high-performance liquid chromatography-mass spectrometry. High concentrations of FTC, DRV, and TFV were detectable in urine at least 24 h after dosing. FTC, DRV, and EVG remained detectable in DBS at least 24 h postdose. FTC and DRV were detectable on buccal swabs up to 2 and 24 h postdose, respectively. TFV was not detectable in DBS or buccal swabs collected between 2 and 96 h after dosing. Variable distribution of ARVs in minimally invasive specimens highlights the challenge of developing POC assays for recent ARV exposure.


  • Antiretroviral drug exposure in urethral and glans surface sampling of the penis

    by Richard E. Haaland, Jeffrey Fountain, Chuong Dinh, L. Davis Lupo, Amy Martin, Christopher Conway-Washington, LaShonda Hall, Colleen F. Kelley, J. Gerardo Garcia-Lerma, Walid Heneine

    Background: HIV exposure to penile tissues provides a risk of acquisition among men, yet studies evaluating penile antiretroviral (ARV) drug distribution have been lacking. We measured ARVs on urethral and glans surface swabs collected following a dose of tenofovir alafenamide, emtricitabine, elvitegravir, darunavir and cobicistat. Methods: Thirty-five HIV-negative male participants provided urethral swabs, glans swabs, rectal swabs, blood and urine up to 96 h following a single dose of tenofovir alafenamide/emtricitabine/elvitegravir/cobicistat and darunavir. ARVs were measured by liquid chromatography–mass spectrometry with a lower limit of detection (LOD) of 1 ng/swab for swabs and 10 ng/mL for plasma and urine. Concentrations are reported as median and range. Results: Urethral swab emtricitabine and darunavir concentrations peaked at 4 h for emtricitabine (36 ng/swab; 3–307 ng/swab) and 8 h for darunavir (25 ng/swab; 2–52 ng/swab). Glans swab emtricitabine and darunavir concentrations peaked 24 h after dosing (emtricitabine 14 ng/swab, <LOD–328 ng/swab; darunavir 6 ng/swab, <LOD–149 ng/swab). Estimated peak urethral secretion emtricitabine and darunavir concentrations are between 10 and 20 μg/mL, similar to rectal secretions, 4-fold greater than in plasma, but 2-fold lower than in urine. Tenofovir and elvitegravir were detected on less than 20% of urethral or glans swabs collected within 24 h of dosing. Conclusions: We document ARV dosing in the urethra and on the glans surface with high drug concentrations noted for emtricitabine and darunavir and lower tenofovir and elvitegravir concentrations. Data suggest a potential protective role of urethral emtricitabine or darunavir against penile HIV acquisition.


  • Open Access

    HIV antiretroviral therapy and prevention use in US blood donors: a new blood safety concern

    by Brian Custer, Claire Quiner, Richard Haaland, Amy Martin, Mars Stone, Rita Reik, Whitney R. Steele, Debra Kessler, Phillip C. Williamson, Steven A. Anderson, et al.

    Antiretroviral therapy (ART) to treat and pre-exposure prophylaxis (PrEP) to prevent HIV infection are effective tools to help end the HIV epidemic. However, their use could affect HIV transfusion-transmission risk. Three different ART/PrEP prevalence analyses in blood donors were conducted. First, blood samples from HIV-positive and a comparison group of infection-nonreactive donors were tested under blind using liquid chromatography-tandem mass spectrometry for ART. Second, blood donor samples from infection-nonreactive, 18- to 45-year-old, male, first-time blood donors in 6 US locations were tested for emtricitabine and tenofovir. Third, in men who have sex with men (MSM) participating in the 2017 Centers for Disease Control and Prevention National HIV Behavioral Surveillance (NHBS) from 5 US cities, self-reported PrEP use proximate to donation was assessed. In blind testing, no ART was detected in 300 infection-nonreactive donor samples, but in 299 HIV confirmed-infected donor samples, 46 (15.4%; 95% confidence interval [CI], 11.5% to 20.0%) had evidence of ART. Of the 1494 samples tested from first-time male donors, 9 (0.6%; 95% CI, 0.03% to 1.1%) had tenofovir and emtricitabine. In the NHBS MSM survey, 27 of 591 respondents (4.8%; 95% CI, 3.2% to 6.9%) reported donating blood in 2016 or 2017 and PrEP use within the same time frame as blood donation. Persons who are HIV positive and taking ART and persons taking PrEP to prevent HIV infection are donating blood. Both situations could lead to increased risk of HIV transfusion transmission if blood screening assays are unable to detect HIV in donations from infected donors.


  • Brief Report: Urine Emtricitabine and Tenofovir Concentrations Provide Markers of Recent Antiretroviral Drug Exposure Among HIV-Negative Men Who Have Sex With Men

    by Richard E. Haaland, Amy Martin, Tamee Bs Livermont, Jeffrey Bs Fountain, Chuong Dinh, Angela Holder, Lindsey D. Lupo, LaShonda Hall, Christopher Bs Conway-Washington, Colleen F. Kelley

    Background: Urine provides a minimally invasive specimen that may allow for development of rapid tests to detect antiretroviral drugs and provide opportunities to improve individual adherence. This study sought to determine whether urine could provide a biomarker of adherence for currently approved pre-exposure prophylaxis and HIV treatment regimens. Methods: Urine and blood were collected from 34 HIV-negative men who have sex with men aged 18–49 years, enrolled in a clinical trial comparing 2 antiretroviral regimens. Specimens were collected 4 and 24 hours after a single oral dose of tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) (n = 10) or tenofovir alafenamide (TAF)/FTC/cobicistat (COBI)/elvitegravir (EVG) (n = 8), or after 4 and 10 days of daily oral TDF/FTC (n = 9) or TAF/FTC/COBI/EVG (n = 7). Tenofovir (TFV), FTC, and EVG were measured by high-performance liquid chromatography-mass spectrometry. Results: Median urine FTC concentrations at 4 and 24 hours were similar between men receiving TDF/FTC (4 hours 147 µg/mL; 24 hours 10 µg/mL) and men receiving TAF/FTC/COBI/EVG (4 hours 333 µg/mL, P = 0.173; 24 hours 13 µg/mL, P = 0.681). Median urine TFV concentrations were lower among men receiving TAF/FTC/COBI/EVG (4 hours 1.2 µg/mL; 24 hours 0.8 µg/mL) compared with men receiving TDF/FTC (4 hours 17 µg/mL, P < 0.001; 24 hours 7 µg/mL, P = 0.001). Urine TFV concentrations remained reduced among men receiving TAF/FTC/COBI/EVG compared with men receiving TDF/FTC after daily dosing. EVG was not consistently measurable in urine. Conclusions: High urine FTC and TFV concentrations could provide an indication of adherence to daily oral dosing with TDF or TAF-based regimens used for treatment and prevention.


  • Open Access

    Short Communication: Reduced Nevirapine Concentrations Among HIV-Positive Women Receiving Mefloquine for Intermittent Preventive Treatment for Malaria Control During Pregnancy

    by Richard E. Haaland, Kephas Otieno, Amy Martin, Abraham Katana, Chuong Dinh, Laurence Slutsker, Clara Menendez, Raquel Gonzalez, John Williamson, Walid Heneine, et al.

    Clinical trials demonstrated intermittent preventive treatment in pregnancy with mefloquine (MQ) reduced malaria rates among pregnant women, yet an unexpected higher risk of mother-to-child transmission (MTCT) of HIV among HIV-positive women receiving MQ has also been observed. To determine if interactions between antiretroviral drugs (ARVs) and MQ could contribute to the increased MTCT observed in women receiving MQ, we performed a retrospective cross-sectional analysis of ARV plasma concentrations in peripheral blood (maternal plasma) and cord blood (cord plasma) collected at delivery from 186 mothers participating in a randomized clinical trial of MQ (n = 102) compared with placebo (n = 84) in Kenya. Plasma zidovudine (AZT), lamivudine (3TC), and nevirapine (NVP) concentrations were measured by high-performance liquid chromatography–tandem mass spectrometry. Although only 4% (7/186) reported not using these ARVs, AZT, 3TC, and NVP were all below the limit of detection in 44% of maternal plasma and 42% of cord plasma samples, and proportions were similar between the two study arms. Median concentrations of AZT and 3TC were not significantly lower in the MQ arm compared with the placebo arm for maternal plasma and cord plasma (p > .05). However, median NVP concentrations were significantly lower in the MQ study arm compared with the placebo study arm in both maternal plasma (1,597 ng/mL vs. 2,353 ng/mL, Mann–Whitney Rank Sum, p = .023) and cord plasma (2,038 ng/mL vs. 2,434 ng/mL, p = .048). Reduced NVP concentrations in maternal and cord plasma of women receiving MQ suggest MQ may affect NVP metabolism for both mother and infant. These results highlight the need to evaluate potential drug–drug interactions between candidate antimalarials and ARVs for use in pregnant women.


  • Open Access

    Repeated rectal application of a hyperosmolar lubricant is associated with microbiota shifts but does not affect PrEP drug concentrations: results from a randomized trial in men who have sex with men

    by Richard E Haaland, Jeffrey Fountain, Yingtian Hu, Angela Holder, Chuong Dinh, LaShonda Hall, Nicole A Pescatore, Sheila Heeke, Clyde E Hart, Jiahui Xu, et al.

    Introduction: Oral pre‐exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) is highly effective in preventing HIV infection among men who have sex with men (MSM). The effects of consistent personal lubricant use in the rectum on tissue PrEP drug concentrations and the rectal microbiota are unknown. We investigated rectal PrEP drug concentrations and the microbiota in MSM before and after repeated rectal application of a hyperosmolar lubricant.Methods: We randomized 60 HIV‐negative MSM to apply 4 mL of hyperosmolar rectal lubricant daily (n = 20), take daily oral TDF/FTC (n = 19), or both (n = 21) for seven days. Blood, rectal biopsies and rectal secretions were collected via rigid sigmoidoscopy before and on day 8 after product use. Tenofovir (TFV) and FTC as well as their intracellular metabolites tenofovir‐diphosphate (TFV‐DP), FTC‐triphosphate (FTC‐TP) were measured by HPLC‐mass spectrometry. Rectal mucosal microbiota was sequenced with 16S rRNA sequencing using Illumina MiSeq.Results: Seven days of lubricant application was not associated with differences in PrEP drug concentrations in rectal tissue or secretions. Lubricant use was associated with a decrease in the relative abundance of the Bacteroides genus (p = 0.01) and a non‐significant increase in the Prevotella genus (p = 0.09) in the rectum. PrEP drug concentrations in rectal tissue and secretions were not associated with microbiota composition or diversity either before or after lubricant use.Conclusions: Repeated rectal application of a hyperosmolar lubricant does not affect mucosal PrEP drug concentrations but is associated with changes in the rectal microbiome.